Bayer AG adds a brand to its US OTC allergy remedy lineup as the Food and Drug Administration adds a first-in-class ingredient to the products it has approved for nonprescription sales with a partial OTC switch of azelastine hydrochloride nasal spray, 0.15%.
OTC Allergy Switch Approved For Bayer In US
Azelastine 0.15% Nasal Antihistamine Branded Astepro Allergy Is First-In-Class Switch
CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.
